Associate Professor, Medicine, Perelman School of Medicine
Oncology
Dr. Ravi Amaravadi, MD
|
|
Give Review
Ravi Amaravadi, MD is an expert in the field of Oncology. He graduated from Johns Hopkins University School of Medicine. Johns Hopkins University School of Medicine is a one of the best medicals schools. Johns Hopkins University School of Medicine is ranked 3 in research and 29 in primary care medicine He received 8 awards: "2011 Most Cited Article in Clinical Cancer Research", "Steinberg Scholar", "CMS Meaningful Use Stage 1 Certification", "Aflac Scholar-In-Training Award", "Merit Award", "Bradley Award for Bench Medicine, Department of Medicine", "Clinical Research Loan Repayment Award" and "Alpha Omega Alpha Honor Society". Ravi Amaravadi, MD is a published doctor as well. He has 39 publications published. The latest was: A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. He is registered with Medicare.
Publications
- A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
- Multiple gastrointestinal polyps in patients treated with BRAF inhibitors.
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in Cancer.
- Autophagy in malignant transformation and Cancer progression.
- BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.
- You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia.
- Identification of secreted proteins that reflect autophagy dynamics within tumor Cells.
- Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells.
- Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib.
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma m...
- Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and Melanoma.
- Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and Melanoma.
- Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory Myeloma.
- Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2.
- PUMA: A Puzzle Piece in Chloroquine's AntiMelanoma Activity.
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma.
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma.
- Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma.
- Autophagy: a targetable linchpin of Cancer cell metabolism.
- Autophagy Inhibition Sensitizes Colon Cancer Cells to Anti-angiogenic and Cytotoxic Therapy.
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of Lymphoma.
- Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor Cell growth.
- Targeted therapy for metastatic Melanoma.
- Targeting the Cell death-survival equation.
- The roles of therapy-induced autophagy and necrosis in Cancer treatment.
- The MAPK pathway in Melanoma.
- Acute pancreatitis associated with rofecoxib.
- Autophagy-induced tumor dormancy in ovarian Cancer.
- Drug targeting of oncogenic pathways in Melanoma.
- Measurements of tumor Cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
- Principles and current strategies for targeting autophagy for Cancer treatment.
- Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome.
- Cancer. Autophagy in tumor immunity.
- Survival in BRAF V600-mutant advanced Melanoma treated with vemurafenib.
- ICU nurse-to-patient ratio is associated with complications and resource use after esophagectomy.
- Autophagy can contribute to Cell death when combining targeted therapy.
- The survival kinases Akt and Pim as potential pharmacological targets.
- Effectively targeting BRAF in Melanoma: a formidable challenge.
Schools
Johns Hopkins University School Of Medicine
Brigham and Women39s Hospital
University Of Pa Health System
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Personal Choice PPO
- Regional Pref Network EPO
- Regional Pref Network HMO
- Regional Pref Network HMO+
- Regional Pref Network POS+
- Regional Pref Network PPO
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- Geisinger Health Plan
- HealthPartners
- Community Blue PPO
- Direct Access
- Horizon Blue Cross Blue Shield HMO
- Horizon Blue Cross Blue Shield POS
- Horizon Blue Cross Blue Shield PPO
- Choice Care PPO
- Keystone Health Plan East HMO
- Medicare MCR
- Freedom Plan
- QualCare HMO
- QualCare PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- Oxford Liberty
- United Healthcare
Awards
- 2011 Most Cited Article in Clinical Cancer Research
- Steinberg Scholar
- CMS Meaningful Use Stage 1 Certification
- Aflac Scholar-In-Training Award
- Merit Award
- Bradley Award for Bench Medicine, Department of Medicine
- Clinical Research Loan Repayment Award
- Alpha Omega Alpha Honor Society
Education
-
University of Pennsylvania Health System -
Brigham and Women's Hospital -
Johns Hopkins University School of Medicine
Hospital
-
Hospital of the University of Pennsylvania -
Penn Presbyterian Medical Center
Drug Facts
| NPI NUMBER | 1043252455 | |
| NPPES Provider LastName | AMARAVADI | |
| NPPES Provider FirstName | RAVI | |
| NPPES Provider ZIPCode | 19104 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 69.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1043252455 |
| Last Name Of The Provider | AMARAVADI |
| First Name Of The Provider | RAVI |
| View All |
Similar Doctors
|
|
Lindsay R. Wilde
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramona F. Swaby, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Wafik El Deiry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin P. Carroll, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Sklaroff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Esha Kaul, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Linda S. Lee, MD |
|
|
Dr. Vikram R. Paralkar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James A. Hoxie, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Lee P. Schacter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey G. Rosenstock, MD
This Doctor is OpenDoctor Recommended.
|